子宫内膜异位症 中国就医指南

Endometriosis is a chronic, estrogen-dependent gynecological disorder characterized by the presence of endometrial-like tissue—glands and stroma—outside the uterine cavity. This ectopic tissue most commonly implants on the ovaries, fallopian tubes, pelvic peritoneum, uterosacral ligaments, and rectovaginal septum; less frequently, it may involve distant sites such as the lungs, diaphragm, or abdominal scars. The disease is associated with inflammation, fibrosis, adhesion formation, and cyclic bleeding—leading to progressive pelvic pain, infertility, and organ dysfunction. Pathogenesis remains incompletely understood but involves multiple interrelated mechanisms: retrograde menstruation (with impaired immune clearance), coelomic metaplasia, lymphatic/vascular dissemination, stem cell recruitment, and genetic-epigenetic dysregulation. Recent evidence highlights aberrant neuroangiogenesis, macrophage polarization defects, and progesterone resistance as key contributors to lesion survival and symptom persistence. Epidemiologically, endometriosis affects approximately 6–10% of reproductive-age women globally—translating to over 190 million individuals. Among women with chronic pelvic pain, prevalence rises to 30–50%; among those with infertility, it reaches 25–50%. Risk factors include early menarche, short menstrual cycles (<27 days), heavy or prolonged menses, nulliparity, low body mass index (BMI), family history (first-degree relatives increase risk 7-fold), and certain genetic variants (e.g., SNPs in WNT4, GREB1, FN1). Protective factors include multiparity, late menarche, and long-term combined oral contraceptive use. Endometriosis profoundly impairs quality of life: 70–90% of affected women report moderate-to-severe dysmenorrhea, 50–70% experience deep dyspareunia, and 30–40% suffer chronic non-cyclical pelvic pain. Fatigue, gastrointestinal symptoms (bloating, diarrhea, constipation—often misdiagnosed as IBS), urinary urgency, and depression/anxiety are highly prevalent. Up to 40% report work absenteeism or reduced productivity; many delay diagnosis by 6–10 years due to normalization of pain and fragmented care pathways. The condition also correlates with increased risks of autoimmune disorders (e.g., SLE, Hashimoto’s thyroiditis), ovarian cancer (particularly clear-cell and endometrioid subtypes), and cardiovascular morbidity later in life. Early recognition, multidisciplinary management—including reproductive endocrinology, pain medicine, colorectal surgery, and urology—is essential to mitigate long-term sequelae and preserve fertility.

# 子宫内膜异位症治疗方案与费用明细（生殖医学科）

一、非手术保守治疗

适用人群：轻中度疼痛、无明显不孕、希望保留生育功能者

• •药物治疗：

- 地诺孕尔酮（曲普瑞林缓释剂）：1980–2380元/支（3.75mg），共3–6针 - 检查费（B超+CA125+性激素六项）：320–450元

二、手术治疗（腹腔镜为核心）

适用人群：中重度疼痛、卵巢巧克力囊肿≥4cm、合并不孕或药物无效者

• •腹腔镜病灶切除术（含粘连松解+囊肿剥除）：

- 术前检查（盆腔MRI+心电图+血常规+凝血功能等）：1,200–1,800元

• •深部浸润型（DIE）复杂病灶处理：25,000–42,000元（含术中神经监测、直肠/输尿管联合探查）

三、特殊复杂情况

• •复发性/耐药性病例（≥2次手术或激素抵抗）：加用GnRH-a维持治疗（6–12个月），总费用3.2–5.8万元
• •合并严重盆腔粘连或肠/膀胱侵犯：需多学科协作（妇科+普外科/泌尿外科），费用45,000–78,000元

四、方案快速选择指南

• •预算≤1万元+症状轻：首选药物保守治疗
• •有生育需求+囊肿≥4cm：推荐腹腔镜微创手术（术后自然试孕或辅助生殖衔接）
• •反复复发/严重影响生活质量：建议DIE专项手术+长期管理（GnRH-a序贯）